324 filings
Page 3 of 17
8-K
a4oh9oj
17 Feb 22
PolarityTE Announces Allowance of Fourth U.S. Patent
8:00am
8-K
usdvy7iz vcomwq9
11 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
wsoxull1r4
18 Jan 22
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
8:00am
8-K
3d9 yqxj1d
23 Dec 21
Departure of Directors or Certain Officers
4:30pm
8-K
5hvtngj9rt
20 Dec 21
PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
8:00am
8-K
ytpzlgrzss0
17 Dec 21
Entry into a Material Definitive Agreement
5:00pm
8-K
ezzi7y0m 2c
10 Nov 21
PolarityTE Reports Third Quarter Financial Results and Provides Business Update
7:00am
8-K
krn89levg7qy0on3
7 Oct 21
PolarityTE Provides Update on Investigational New Drug Application
8:00am
8-K
ro8hxxgx6u
1 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
jmzfsk09
9 Sep 21
Regulation FD Disclosure
8:01am
8-K
lfdv7voc9vkc
2 Sep 21
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg
8:00am
8-K
ja3bbwjin0dzejv
27 Aug 21
Departure of Directors or Certain Officers
12:00am
8-K
0eswg ux0
24 Aug 21
Departure of Directors or Certain Officers
8:00am
8-K
lbwox5kc
16 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
kh3jvjpcf99 nlyr
12 Aug 21
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
4:00pm
8-K
l8mb6u026xl4zn
28 Jul 21
Regulation FD Disclosure
8:00am
8-K
8g4 gmz1v3wsp6i
26 Jul 21
Other Events
8:00am
8-K
2aww2ov
12 Jul 21
PolarityTE Receives Notice of Allowance for Chinese Patent
8:00am
8-K
sokndzdv
17 Jun 21
Termination of a Material Definitive Agreement
4:45pm
8-K
rocsnm8arkzr8bv
13 May 21
PolarityTE Reports First Quarter Results and Provides Business Update
4:26pm